AU2016379425B2 - Methods of treating cancer - Google Patents

Methods of treating cancer Download PDF

Info

Publication number
AU2016379425B2
AU2016379425B2 AU2016379425A AU2016379425A AU2016379425B2 AU 2016379425 B2 AU2016379425 B2 AU 2016379425B2 AU 2016379425 A AU2016379425 A AU 2016379425A AU 2016379425 A AU2016379425 A AU 2016379425A AU 2016379425 B2 AU2016379425 B2 AU 2016379425B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
cancer
receptor antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016379425A
Other languages
English (en)
Other versions
AU2016379425A1 (en
Inventor
Po Y. Ho
Andrew Hotson
Ian Mccaffery
Richard A. Miller
Stephen WILLINGHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corvus Pharmaceuticals Inc
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of AU2016379425A1 publication Critical patent/AU2016379425A1/en
Application granted granted Critical
Publication of AU2016379425B2 publication Critical patent/AU2016379425B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016379425A 2015-12-24 2016-12-22 Methods of treating cancer Active AU2016379425B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562387383P 2015-12-24 2015-12-24
US62/387,383 2015-12-24
US201662324211P 2016-04-18 2016-04-18
US62/324,211 2016-04-18
US201662350602P 2016-06-15 2016-06-15
US62/350,602 2016-06-15
US201662421171P 2016-11-11 2016-11-11
US201662421109P 2016-11-11 2016-11-11
US62/421,171 2016-11-11
US62/421,109 2016-11-11
PCT/US2016/068459 WO2017112917A1 (en) 2015-12-24 2016-12-22 Methods of treating cancer

Publications (2)

Publication Number Publication Date
AU2016379425A1 AU2016379425A1 (en) 2018-07-12
AU2016379425B2 true AU2016379425B2 (en) 2021-11-11

Family

ID=59091273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016379425A Active AU2016379425B2 (en) 2015-12-24 2016-12-22 Methods of treating cancer

Country Status (13)

Country Link
US (2) US10912776B2 (2)
EP (1) EP3393475B1 (2)
JP (1) JP6847958B2 (2)
KR (1) KR20180103918A (2)
CN (1) CN108883107A (2)
AU (1) AU2016379425B2 (2)
CA (1) CA3009527C (2)
EA (1) EA201891509A1 (2)
ES (1) ES3017686T3 (2)
IL (1) IL260199B (2)
MX (1) MX391382B (2)
WO (1) WO2017112917A1 (2)
ZA (1) ZA201804227B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3393475B1 (en) * 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
EP3606531A4 (en) 2017-04-04 2021-04-28 Corvus Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
EP3668517A4 (en) * 2017-08-14 2021-02-17 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
CN109662966A (zh) * 2017-10-16 2019-04-23 北京莱科金基因科技有限责任公司 伊曲茶碱在制备用于肿瘤治疗的药物中的用途
CN111587113A (zh) * 2017-11-06 2020-08-25 科尔沃斯制药股份有限公司 用于癌症治疗的组合疗法
KR20200096921A (ko) * 2017-11-06 2020-08-14 코버스 파마슈티칼스, 인크. 암 치료를 위한 아데노신 경로 억제제
WO2019152798A1 (en) * 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
EP3520782A3 (en) 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3100923A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US12116635B2 (en) * 2018-07-12 2024-10-15 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US12174192B2 (en) * 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20200105246A (ko) * 2019-02-28 2020-09-07 한미약품 주식회사 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
CN112028891B (zh) * 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂
KR20220105160A (ko) * 2019-11-26 2022-07-26 아스트라제네카 아베 암의 치료 방법
BR112022011235A2 (pt) * 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
US20210205311A1 (en) * 2020-01-03 2021-07-08 Incyte Corporation Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
KR20230147617A (ko) * 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
CN116898858B (zh) * 2023-08-11 2025-09-23 锦州医科大学 一种治疗非小细胞肺癌的药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172252A1 (en) * 2008-06-25 2011-07-14 Vernalis Research Limited Triazolo[4,5-d]pyramidine derivatives and their use as purine receptor antagonists

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
EP3393475B1 (en) * 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
EP3606531A4 (en) * 2017-04-04 2021-04-28 Corvus Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER
KR20200096921A (ko) * 2017-11-06 2020-08-14 코버스 파마슈티칼스, 인크. 암 치료를 위한 아데노신 경로 억제제
WO2019152798A1 (en) * 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172252A1 (en) * 2008-06-25 2011-07-14 Vernalis Research Limited Triazolo[4,5-d]pyramidine derivatives and their use as purine receptor antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HERBST R. S. et al., "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", NATURE, (2014), vol. 515, no. 7528, pages 563 - 567 *
MAHONEY K. M. et al., "Combination cancer immunotherapy and new immunomodulatory targets", NATURE REVIEWS DRUG DISCOVERY, (2015), vol. 14, pages 561 - 585 *
MEDIAVILLA-VARELA M. et al., "Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth", CANCER BIOLOGY & THERAPY, (2013), vol. 14, no. 9, pages 860 - 868 *
MITTAL D. et al., "Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor", CANCER RESEARCH, (2014), vol. 74, no. 14, pages 3652 - 3658 *
POWLES T. et al., "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer", NATURE, (2014), vol. 515, no. 7528, pages 558 - 562 *

Also Published As

Publication number Publication date
IL260199B (en) 2022-01-01
US20210154199A1 (en) 2021-05-27
WO2017112917A1 (en) 2017-06-29
EP3393475B1 (en) 2025-02-05
CA3009527A1 (en) 2017-06-29
ZA201804227B (en) 2022-07-27
AU2016379425A1 (en) 2018-07-12
EP3393475A1 (en) 2018-10-31
US20190076433A1 (en) 2019-03-14
JP2019503365A (ja) 2019-02-07
CN108883107A (zh) 2018-11-23
IL260199A (en) 2018-07-31
JP6847958B2 (ja) 2021-03-24
EP3393475C0 (en) 2025-02-05
KR20180103918A (ko) 2018-09-19
WO2017112917A8 (en) 2018-07-26
ES3017686T3 (en) 2025-05-13
EA201891509A1 (ru) 2019-01-31
US12023337B2 (en) 2024-07-02
MX391382B (es) 2025-03-21
US10912776B2 (en) 2021-02-09
EP3393475A4 (en) 2019-08-14
CA3009527C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
US12023337B2 (en) Methods of treating cancer
US20240115700A1 (en) Cancer treatment combinations
US20190022096A1 (en) Methods of treating cancer
US20230066830A1 (en) Methods and compositions for inducing apoptosis in cancer stem cells
CA3080994A1 (en) Combination therapy for cancer treatment
CA3029003C (en) Cancer treatment combinations
HK1263152A1 (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
HK1263152B (en) Ciforadent alone or in combination with atezolizumab for use in treating cancer
NZ743653A (en) Methods of treating cancer
HK40010265A (en) Cancer treatment combinations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)